VKTX

30.29

2.16% 0.64

Vorhandelsmarkt: 30.50 0.21 +0.69%

Viking Therapeutics Inc (VKTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VKTX? Forum Prognose

Schlusskurs vom Vortag:

$29.65

Offen:

$30

24-Stunden-Volumen:

1.88M

Relative Volume:

0.86

Marktkapitalisierung:

$3.52B

Einnahmen:

Nettoeinkommen (Verlust:

$-472.34M

KGV:

-7.306

EPS:

-4.1459

Netto-Cashflow:

$-340.33M

1W Leistung:

+9.15%

1M Leistung:

+0.07%

6M Leistung:

-11.69%

1J Leistung:

+14.60%

1-Tages-Spanne:

$29.60

$31.27

1-Wochen-Bereich:

$27.16

$31.27

52-Wochen-Spanne:

$22.96

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Firmenname

Viking Therapeutics Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

858-704-4660

Adresse

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Mitarbeiter

Twitter

@viking_vktx

Nächster Verdiensttermin

2026-07-22

Neueste SEC-Einreichungen

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VKTX Viking Therapeutics Inc	30.29	3.44B	0	-472.34M	-340.33M	-4.1459
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-26	Eingeleitet	Wolfe Research	Peer Perform
2025-10-29	Eingeleitet	Canaccord Genuity	Buy
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-04-08	Eingeleitet	Goldman	Neutral
2025-02-13	Eingeleitet	Scotiabank	Sector Outperform
2025-02-07	Eingeleitet	Citigroup	Neutral
2024-12-02	Eingeleitet	Piper Sandler	Overweight
2024-11-22	Eingeleitet	B. Riley Securities	Buy
2024-11-04	Bestätigt	H.C. Wainwright	Buy
2024-09-11	Eingeleitet	JP Morgan	Overweight
2024-06-27	Eingeleitet	Morgan Stanley	Overweight
2024-05-16	Hochstufung	Raymond James	Outperform → Strong Buy
2024-03-26	Bestätigt	Oppenheimer	Outperform
2024-03-07	Eingeleitet	Jefferies	Buy
2024-02-28	Bestätigt	Oppenheimer	Outperform
2023-05-31	Fortgesetzt	ROTH MKM	Buy
2023-03-28	Bestätigt	Maxim Group	Buy
2023-03-17	Eingeleitet	Stifel	Buy
2021-07-29	Fortgesetzt	BTIG Research	Buy
2021-05-25	Herabstufung	Raymond James	Strong Buy → Outperform
2020-06-05	Eingeleitet	BMO Capital Markets	Outperform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-05-01	Eingeleitet	BTIG Research	Buy
2019-07-16	Eingeleitet	Oppenheimer	Outperform
2019-06-25	Eingeleitet	Stifel	Buy
2019-03-29	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-03-14	Bestätigt	Maxim Group	Buy
2019-02-22	Eingeleitet	SVB Leerink	Mkt Perform
2018-12-12	Eingeleitet	B. Riley FBR	Buy
2018-11-19	Hochstufung	Raymond James	Outperform → Strong Buy
2018-09-18	Bestätigt	H.C. Wainwright	Buy
2018-09-18	Bestätigt	Maxim Group	Buy
2018-09-18	Bestätigt	Raymond James	Outperform
2018-07-20	Eingeleitet	SunTrust	Buy
2018-06-28	Eingeleitet	Raymond James	Outperform
2018-06-01	Bestätigt	Laidlaw	Buy
2018-05-31	Bestätigt	Maxim Group	Buy
2018-03-26	Fortgesetzt	H.C. Wainwright	Buy
2017-11-28	Bestätigt	Maxim Group	Buy
2017-11-21	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

Jun 15, 2026

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits

Jun 15, 2026

Jun 14, 2026

VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits

Jun 14, 2026

Jun 13, 2026

VKTX Technical Analysis & Stock Price Forecast - Intellectia AI

Jun 13, 2026

Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized - Sahm

Jun 13, 2026

Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)? - simplywall.st

Jun 13, 2026

Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation - Yahoo Finance

Jun 12, 2026

VKTX Stock Price, Quote & Chart - ChartMill

Jun 12, 2026

Is Viking Therapeutics Stock Going to $100? - The Motley Fool

Jun 12, 2026

Jun 11, 2026

VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits

Jun 11, 2026

VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits

Jun 11, 2026

Viking Therapeutics Taps Hubert Chen as Chief Medical Officer - Contract Pharma

Jun 11, 2026

Viking Therapeutics (VKTX) Appoints New Chief Medical Officer - GuruFocus

Jun 11, 2026

Viking Therapeutics Appoints Hubert C. Chen, M.D., as Chief Medical Officer - marketscreener.com

Jun 11, 2026

Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com - Investing.com Nigeria

Jun 11, 2026

Viking Therapeutics Appoints Hubert Chen as Chief Medical Officer - citybiz

Jun 11, 2026

Viking Therapeutics appoints Hubert Chen as chief medical officer - Investing.com

Jun 11, 2026

Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer - TradingView

Jun 11, 2026

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - PR Newswire

Jun 11, 2026

Why 1 Wall Street analyst thinks Viking Therapeutics stock could soar 188% - MSN

Jun 11, 2026

VKTX eyes worst week since November as trial data looms — Wall Street still sees 200% upside - MSN

Jun 11, 2026

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock - AOL.com

Jun 11, 2026

Jun 10, 2026

Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks - NAI500

Jun 10, 2026